The detection and isolation of CTCs in BC patients are generally based on the selection of specific epithelial markers, such as EpCAM (mainly), CK8, CK18, and CK19, and the exclusion of leukocytes by CD45, through fluorescence-labeled monoclonal antibodies [57,59,67]. The gene discussed is KRT19; the disease is breast cancer.